CVS warns about PBM reforms leading to 'higher costs'; Ezekiel Emanuel on out-of-pocket costs for cancer care

Taking stock of the drug industry, from the lab to the medicine chest

May 31, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Justin Sullivan/Getty Images STAT+ | CVS warns PBM reforms 'could lead to higher costs' A top executive at CVS Health said the company would find ways to maintain its level of PBM profits if Congress makes reforms. By Bob Herman Opinion: Listen: Ezekiel Emanuel explains why cancer patients shouldn't pay out-of-pocket costs Financial toxicity doesn't just set cancer patients back economically. It actually hurts their health, and even costs lives. By Torie Bosch House Republicans demand career scientist explain pathogen research Republicans want a career scientist to explain his work, stoking a long-running argument about gain-of-function research. By Sarah Owermohle Adobe Opinion: Newly diagnosed cancer patients need help navigating the system Cancer navigation support is a rare intervention that truly seems to achieve a win for every stakeholder – patients, providers, and payers. By Samyukta Mullangi and Vinayak Venkataraman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser